ImmuPharma PLC (GB:IMM)
LSE:IMM
Want to see GB:IMM full AI Analyst Report?
IMM Stock Chart & Stats
6.20 p
0.95 p(79.03%)
At close: 4:00 PM EST
6.20 p
0.95 p(79.03%)
Day’s Range― - ―
52-Week Range1.39 p - 19.40 p
Previous CloseN/A
Volume11.77M
Average Volume (3M)15.00M
Market Cap
£27.02M
Enterprise Value20.26M
Total Cash (Recent Filing)£1.35M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding623,911,400
10 Day Avg. Volume4,827,745
30 Day Avg. Volume14,996,625
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)44.28
Price to Sales (P/S)0.00
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageReported near-zero debt materially lowers financial risk over the medium term: the company has minimal interest burden and less refinancing pressure, which gives management optionality to fund clinical programs or seek strategic partnerships without immediate solvency risk.
Narrowing Losses / Cost ControlA multi-year reduction in losses indicates durable cost discipline and a smaller operating footprint, which extends runway per unit of funding and improves the odds that future financings will be smaller or less dilutive if this trend persists alongside focused development milestones.
Focused Clinical-stage R&DA concentrated clinical-stage focus in autoimmune/inflammatory areas creates clear project-level value drivers (trial readouts, regulatory progress, licensing milestones). This asset-centric model can generate high-value binary outcomes and strategic partnerships without the fixed costs of commercialization.
Bears Say
No Recurring RevenueZero recent revenue means the business lacks operating cash inflows and is structurally dependent on external financing or partnerships; over a 2–6 month horizon this elevates dilution and program disruption risk if capital markets or fundraising windows tighten.
Fragile Equity / Capital Structure VolatilityVolatile equity and a previously negative book‑equity position point to a fragile capital base that increases the likelihood of dilution during future raises, reduces creditor confidence, and limits strategic flexibility for licensing or M&A without substantial recapitalization.
Negative Cash Generation / Cash BurnConsistent negative operating and free cash flow creates ongoing financing needs; absent near-term revenue or material partnerships, persistent cash burn risks program delays or funding-driven cutbacks that could impair pipeline progress and long-term value creation.
ImmuPharma News
IMM FAQ
What was ImmuPharma PLC’s price range in the past 12 months?
ImmuPharma PLC lowest share price was 1.39 p and its highest was 19.40 p in the past 12 months.
What is ImmuPharma PLC’s market cap?
ImmuPharma PLC’s market cap is £27.02M.
When is ImmuPharma PLC’s upcoming earnings report date?
ImmuPharma PLC’s upcoming earnings report date is Sep 24, 2026 which is in 107 days.
How were ImmuPharma PLC’s earnings last quarter?
ImmuPharma PLC released its earnings results on May 27, 2026. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is ImmuPharma PLC overvalued?
According to Wall Street analysts ImmuPharma PLC’s price is currently Overvalued.
Does ImmuPharma PLC pay dividends?
ImmuPharma PLC pays a Notavailable dividend of 1 p which represents an annual dividend yield of N/A. See more information on ImmuPharma PLC dividends here
What is ImmuPharma PLC’s EPS estimate?
ImmuPharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuPharma PLC have?
ImmuPharma PLC has 623,911,400 shares outstanding.
What happened to ImmuPharma PLC’s price movement after its last earnings report?
ImmuPharma PLC reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -4.333%.
Which hedge fund is a major shareholder of ImmuPharma PLC?
Currently, no hedge funds are holding shares in GB:IMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ImmuPharma PLC
ImmuPharma plc is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutic solutions. The firm's innovative treatments address a range of medical fields, including autoimmune and inflammatory disorders, as well as anti-infective applications. Leading its pipeline is Lupuzor, an autophagy immunomodulator, which is presently undergoing Phase III clinical trials for the management of lupus, a chronic autoimmune inflammatory disease. Beyond its lead candidate, ImmuPharma is advancing BioAMB, a peptide-based drug designed for Amphotericin-B formulations used against fungal infections caused by the aspergillus family. Another product in development is BioCin, a peptide-based antibacterial agent intended for situations of high medical need and as a last-line defense. The company maintains a collaborative relationship with the Centre National de la Recherche Scientifique to develop a peptide technology platform targeting diabetes through glucagon-like peptide -1 agonists and glucagon antagonists for both type I and type II diabetes. ImmuPharma also holds a license and development agreement with Avion Pharmaceuticals LLC. Founded in 1999, ImmuPharma plc is headquartered in London, United Kingdom.
Technical Analysis
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
SkinBioTherapeutics
―
Poolbeg Pharma Ltd.
―